The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you whenever you need it. Give us a call at 650-498-3333 or GuestServices@stanfordmed.org.
PHYSICIAN HELPLINE
Have a question? We're here to help!
Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
Jeffrey Dunn, MD
Multiple sclerosis specialist
Clinical Professor, Neurology & Neurological Sciences
Jeffrey Dunn, MD, FAAN serves as Professor of Clinical Neurology and Division Chief of Clinical Neuroimmunology in the Department of Neurology and Neurosciences at Stanford University. His clinical focus is conditions in which the immune system interacts with the central nervous system to cause disease. His research employs a collaborative interdisciplinary approach to identify biomarkers of disease status, and to identify potential therapeutic targets for novel drug development. Dr. Dunn has served as Principal Investigator in more than 20 clinical trials of new and emerging treatments for MS, many of which have since been FDA approved for use. Dr. Dunn is an elected Fellow and Vice Chair of the Executive Committee of the MS Section of the American Academy of Neurology. He has been awarded the prestigious Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, and the Arthur Bloomfield Award in recognition of excellence in the teaching of clinical medicine.
- 300 Pasteur Drive
- Stanford, CA 94305
- Phone: 650-723-6469
Conditions Treated
Professional Overview
Professional Education
Residency: University of Washington Medical Center (1989) WA
Internship: Eastern VA Medical School (1989) VA
Medical Education: Temple University School of Medicine (1989) PA
Board Certification: Neurology, American Board of Psychiatry and Neurology (1994)
Residency, University of Washington, Neurology (1993)
M.D., Temple University, Medicine (1989)
B.A., Haverford College, French Literature (1983)
Honors & Awards
Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)
Top Doctors, US News & World Report (2012-2013)
AUPN Neurology national recuitment award, Association of University Professors of Neurology (2012)
Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)
Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
AUPN Neurology Recruitment Award (highest percentage in U.S.), Association of University Professors of Neurology (2011)
Excellence in Neurology Clerkship Teaching Award, Stanford University Department of Neurology & Neurosciences (2008,2009,2010,2011,2012,2013)
Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)
Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)
Fellow, American Academy of Neurology (2008-present)
"America's Top Rated Physicians", Guide to Top Doctors (1998-2007, 2010-2013)
Administrative Appointments
Division Chief, Clinical Neuroimmunology (2009 - Present)
Director, Stanford Multiple Sclerosis Center & Neuroimmunology Clinic (2008 - Present)
Director, Neurology Clerkship Program (2009 - Present)
Vice Chair, MS Section, American Academy of Neurology (2014 - Present)
Chair, MS Education Workgroup, Multiple Sclerosis Section; American Academy of Neurology (2011 - 2014)
Councilor, Executive Committee, Multiple Sclerosis Section; American Academy of Neurology (2010 - 2014)
Patient Ratings and Comments
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Publications
Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis
Lublin, F., & CombiRx Investigators. (2013). Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. Annals of Neurology, 73(3).
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein
Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., & Axtell, R. C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. MULTIPLE SCLEROSIS JOURNAL, 18(4), 398-408.
Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein
Herges K, DeJong BA, Kolkowitz I, Dunn C, Mandelbaum G, & Axtell RC. (2012). Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein. Multiple Sclerosis, 18(4).
Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis
Dunn, J., & Blight, A. (2011). Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. CURRENT MEDICAL RESEARCH AND OPINION, 27(7), 1415-1423.
Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis
Dunn J, & Blight A. (2011). Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis. Current Research Medical Opinion, 27(7).
Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
Dunn, J. (2010). Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 10(4), 433-440.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., & Rose, J. W. (2010). Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. LANCET NEUROLOGY, 9(4), 381-390.
The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
Dunn, J. (2010). The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev. Pharmacoeconomics Outcomes Res., 10(4).
Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts
Pershing, S., Dunn, J., Khan, A., & Liao, Y. J. (2009). Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts. JOURNAL OF NEURO-OPHTHALMOLOGY, 29(3), 223-226.
CMV Optic Neuritis with Extensive Tracking along the Visual Pathway
Pershing S, D. J. K. A. L. Jy. (2009). CMV Optic Neuritis with Extensive Tracking along the Visual Pathway. J Neuro-Ophthalmology, 29(3).
Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis
Vollmer T, P. H. B.-O. A. D. J. F. Ms. G. Sk. C. D. D. F. A. D. (2008). Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis. Multiple Sclerosis, Apr 18.
Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS
Fox, Ej., & The TERMS Study Investigators. (2008). Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS. Multiple Sclerosis, 14.
Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS
Arnold D., C. D. P. H. B.-O. A. D. J. F. M. G. S. K. V. T. (2008). Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol, 255.
Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS
Cohen JA Rovaris M Goodman AD Ladkani D Wynn D Filippi M 9006 Study Group. (2007). Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS. Neurology, 68(12).
Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II
Montalban X, K. M. W. D. et D. J. with the Choice. S. I. (2007). Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II. ECTRIMS, 10/11/07.
Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis
Krupp L, B. B. P. M. D. J. W.-G. B. P. L. (2005). Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis. ECTRIMS/ACTRIMS, (September).
Novantrone in the Treatment of Multiple Sclerosis
Dunn Jeffrey, K. M. L. S. B. J. (2001). Novantrone in the Treatment of Multiple Sclerosis. Alliance News.
Comprehensive Outpatient Management of Patients with Multiple Sclerosis
Odderson I, D. J. (2001). Comprehensive Outpatient Management of Patients with Multiple Sclerosis. RIMS MS Symposium, (May).
Clinical Advisory Committee Statement
Bowen J., D. J. E. K. G. H. R. G. S. J. S. C. T. L. (1999). Clinical Advisory Committee Statement. Health Care Connection, I(1).
Gingko Biloba in the Treatment of Alzheimer's Disease
Dunn Jeffrey E., M. R. P. J. (1998). Gingko Biloba in the Treatment of Alzheimer's Disease. Alternative Medicine, 1(15).
Atherosclerotic Aortic Disease as a Source of Embolic Infarct
Bursell John P., O. I. D. J. E. (1996). Atherosclerotic Aortic Disease as a Source of Embolic Infarct. Journal of Neurovascular Disease, 1(2).
INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., & MILLER, R. A. (1992). INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS. ANNALS OF INTERNAL MEDICINE, 116(9), 740-742.
Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV
Spach, D., Panther L., Thorning D., Dunn Jeffrey E., Plorde J.L., & R. (1992). Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV. Annals of Internal Medicine, 116.
Patient Comments
17 Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Sep 2014
Dr. Dunn always explains my problems in detail - (a great person/doctor.
SHC Patient, Aug 2014
The care and compassion that Dr. Dunn shared with me (and my husband) was very much appreciated!! Thank you.
SHC Patient, Jul 2014
Great doctor!
SHC Patient, Jul 2014
Dr. Dunn & his staff are the ultimate professionals. They are very caring and comforting. They encourage me and give me hope -
SHC Patient, Jul 2014
Again - I just wish we could have seen images at initial visit instead had to come back for follow up which was very inconvenient.
SHC Patient, Jun 2014
Dr. Dunn is an outstanding doctor and I am fortunate to be able to be under his care.
SHC Patient, May 2014
Dr. Dunn was fantastic! He spent more time with me and I never felt he was rushed. Very thorough. Superb clinical acumen.
SHC Patient, May 2014
Dr. Dunn is very good at what he does.
SHC Patient, May 2014
Dr. Dunn was very informative, thoughtful, and sincere.
SHC Patient, Mar 2014
Wonderful doc - knows his stuff - very kind - he is wroth the wait.
SHC Patient, Mar 2014
Jeff Dunn is the best doctor - absolute trust in him -
SHC Patient, Mar 2014
Dr. Dunn is very friendly and very good at explaining my condition to me.
SHC Patient, Feb 2014
Dr. Dunn is the best doctor ever!
SHC Patient, Dec 2013
I felt in the best of care -
SHC Patient, Dec 2013
Extremely good! Very respectful of me & my illness.
SHC Patient, Dec 2013
Excellent staff! Very clean office.
SHC Patient, Dec 2013
Dr. Dunn made me feel well taken care of. I slept well for the 1st time in many weeks after that appt.